Abstract: Objective To investigate the effect of amiodarone hydrochloride and potassium magnesium aspartate in combination on efficacy and incidence of cardiogenic events in acute myocardial infarction patients complicating with malignant arrhythmia. Methods Seventy-eight acute myocardial infarction patients complicating with malignant arrhythmia were selected as research objects and were divided into control group and study group according to the random throwing method. The control group was treated with amiodarone hydrochloride on the basis of conventional treatment, while the study group was additionally treated with potassium magnesium aspartate on the basis of the control group. The clinical efficacy, cardiac function grading and cardiac function index before and after treatment, and the incidence of cardiogenic events in the two groups were compared. Results The total effective rate in the study group was 92.31%, which was significantly higher than 74.36%in the control group(P<0.05); there were no significant differences in the proportion of patients with grade Ⅱand Ⅳ of cardiac function after treatment between the two groups(P>0.05). The ratio of patients with grade Ⅰ of heart function was significantly higher, and ratio of patients with grade Ⅲof heart function was significantly lower than that in the control group(P<0.05). Before treatment, levels of cardiac stroke volume(SV), left ventricular ejection fraction(LVEF), cardiac troponin I(cTnI)in the two groups showed no significant differences(P>0.05); after treatment, levels of SV and LVEF in the study group were significantly higher than that in the control group, and cTnl level was significantly - lower than that in the control group(P<0.05); the incidence of cardiogenic events in the study group was 10.26%, which was lower than 28.21% of the control group(P<0.05). Conclusion Amiodarone hydrochloride and potassium magnesium aspartate in combination has significant effect in the treatment of acute myocardial infarction and malignant arrhythmia, which can improve the heart function and reduce the incidence of cardiogenic events.